ZA968783B - Flupirtine usage - Google Patents

Flupirtine usage

Info

Publication number
ZA968783B
ZA968783B ZA968783A ZA968783A ZA968783B ZA 968783 B ZA968783 B ZA 968783B ZA 968783 A ZA968783 A ZA 968783A ZA 968783 A ZA968783 A ZA 968783A ZA 968783 B ZA968783 B ZA 968783B
Authority
ZA
South Africa
Prior art keywords
flupirtine
usage
patients
prophylaxis
impairment
Prior art date
Application number
ZA968783A
Other languages
English (en)
Inventor
Gabriela Dr Pergande
Werner E G Prof Mueller
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of ZA968783B publication Critical patent/ZA968783B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA968783A 1995-11-07 1996-10-18 Flupirtine usage ZA968783B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19541405A DE19541405A1 (de) 1995-11-07 1995-11-07 Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen

Publications (1)

Publication Number Publication Date
ZA968783B true ZA968783B (en) 1997-05-27

Family

ID=7776799

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA968783A ZA968783B (en) 1995-11-07 1996-10-18 Flupirtine usage

Country Status (26)

Country Link
US (2) US6034111A (cs)
EP (1) EP0859613B1 (cs)
JP (1) JPH11514652A (cs)
KR (1) KR100512673B1 (cs)
CN (1) CN1116037C (cs)
AT (1) ATE316789T1 (cs)
AU (1) AU711207B2 (cs)
BG (1) BG63149B1 (cs)
BR (1) BR9611588A (cs)
CA (1) CA2189705C (cs)
CZ (1) CZ298115B6 (cs)
DE (2) DE19541405A1 (cs)
DK (1) DK0859613T3 (cs)
ES (1) ES2257755T3 (cs)
HU (1) HU225742B1 (cs)
MX (1) MX9803610A (cs)
NO (1) NO315074B1 (cs)
NZ (1) NZ330414A (cs)
PL (1) PL186537B1 (cs)
PT (1) PT859613E (cs)
RU (1) RU2200555C2 (cs)
SK (1) SK284601B6 (cs)
TW (1) TW393317B (cs)
UA (1) UA51682C2 (cs)
WO (1) WO1997017072A2 (cs)
ZA (1) ZA968783B (cs)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102009023162B4 (de) * 2009-05-29 2011-07-07 Corden PharmaChem GmbH, 68305 Verfahren zur Herstellung von Flupirtin
US9212416B2 (en) * 2009-08-07 2015-12-15 Swagelok Company Low temperature carburization under soft vacuum
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
CN104302277A (zh) * 2012-03-02 2015-01-21 Meda制药有限及两合公司 含有氟吡汀的药物制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN172468B (cs) * 1990-07-14 1993-08-14 Asta Medica Ag
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin

Also Published As

Publication number Publication date
EP0859613B1 (de) 2006-02-01
US6034111A (en) 2000-03-07
HUP9901659A3 (en) 2001-04-28
PL186537B1 (pl) 2004-01-30
WO1997017072A3 (de) 1997-07-24
NO315074B1 (no) 2003-07-07
PL326629A1 (en) 1998-10-12
CA2189705C (en) 2005-08-09
HUP9901659A2 (hu) 1999-09-28
BR9611588A (pt) 1999-04-06
EP0859613A2 (de) 1998-08-26
US6034112A (en) 2000-03-07
CN1201391A (zh) 1998-12-09
MX9803610A (es) 1998-09-30
AU1716597A (en) 1997-05-29
CA2189705A1 (en) 1997-05-08
AU711207B2 (en) 1999-10-07
HU225742B1 (en) 2007-07-30
DE59611327D1 (de) 2006-04-13
PT859613E (pt) 2006-06-30
CN1116037C (zh) 2003-07-30
DE19541405A1 (de) 1997-05-15
UA51682C2 (uk) 2002-12-16
CZ128398A3 (cs) 1998-09-16
KR100512673B1 (ko) 2005-12-09
CZ298115B6 (cs) 2007-06-27
SK58698A3 (en) 1998-09-09
DK0859613T3 (da) 2006-06-06
WO1997017072A2 (de) 1997-05-15
TW393317B (en) 2000-06-11
HK1016508A1 (en) 1999-11-05
RU2200555C2 (ru) 2003-03-20
NO981898D0 (no) 1998-04-27
NZ330414A (en) 1999-10-28
KR19990067366A (ko) 1999-08-16
ATE316789T1 (de) 2006-02-15
JPH11514652A (ja) 1999-12-14
NO981898L (no) 1998-04-27
SK284601B6 (sk) 2005-07-01
ES2257755T3 (es) 2006-08-01
BG102404A (en) 1998-12-30
BG63149B1 (bg) 2001-05-31

Similar Documents

Publication Publication Date Title
AU586860B2 (en) Therapeutical application of phosphonylmethoxyalkyl adenines
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
TW371660B (en) Therapeutic nucleosides a purine carbocyclic nucleosides for treatment of HIV and HBV infections
YU18899A (sh) L-nukleozidi purina, njihovi analogoni i primena
MY117892A (en) Therapeutic compounds
IE900073L (en) Treatment of diseases associated with hiv infections
ZA968783B (en) Flupirtine usage
AP9801286A0 (en) Therapeutic compounds.
MY105855A (en) Therapeutic nucleotides.
NZ512850A (en) Treatment of papillomavirus infections
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
AU2880595A (en) Use of pharmaceutical agents for restoring, alleviation, or treatment of immunodeficiency, including the alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses
AU4111600A (en) The use of gssg reductase for the therapy and prophylaxis of hiv infected patients
MX9700560A (es) Metodo de uso de integrasa retroviral negativa transdominante en el tratamiento de infecciones retrovirales.
AU5535498A (en) Treatment of HIV positive patients
WO1997026880A3 (en) Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients
AU2396900A (en) Treatment and prevention of hiv and other viral infections
AU2211592A (en) Method of treatment for latent virus infection
MD1051C2 (ro) Remediu antiherpetic
AU2450900A (en) Therapeutic nucleoside compound
ES8700940A1 (es) Procedimiento de obtencion de composiciones para el trata- miento de infecciones por rinovirus
WO1988008707A3 (en) Rubradirin derivatives for treatment of hiv infection
GR1002968B (el) Φαρμακευτικο παρασκευασμα βασιζομενο σε εναιωρημα εμβρυικων κυτταρων με ανοσοδιορθωτικη δραση και μεθοδος θεραπειας ζαχαρωδους διαβητη με τη χρηση αυτου του παρασκευασματος.
MX9503363A (es) N-(2,6-dioxo-3-piperidil) ftalimida (generico talidomida como tratamiento del sindrome de desgaste asociado con la infeccion por vih-1.
AU2880495A (en) Use of pharmaceutical agents for alleviation or treatment of the immune dysfunction related to infection with human immunodeficiency viruses (hiv) or related viruses